Filtered By:
Condition: Diabetes
Drug: Actos
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 116 results found since Jan 2013.
Observational follow‐up of the PROactive study: a 6‐year update†
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: E. Erdmann, E. Song, R. Spanheimer, A.‐R. van Troostenburg de Bruyn, A. Perez Tags: ORIGINAL ARTICLE Source Type: research
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM), are at least 50 years old, have cardiovascular disease, and have an hemoglobin A1c value between 6.5% and 8.0%. Eligible participan...
Source: American Heart Journal - October 25, 2013 Category: Cardiology Authors: Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman Tags: Trial Design Source Type: research
Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia
Conclusions
Because of the higher prevalence of abnormal cognition in aged outpatients with diabetes found in primary care practice and significant associations with serum albumin, uric acid, renal function, retinopathy and antidiabetic drugs, there is a need for early diagnosis and strategies against dementia.
Source: Diabetology International - November 9, 2014 Category: Endocrinology Source Type: research
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research
Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers.
CONCLUSIONS: Pioglitazone is endowed with neuroprotective properties which are probably mediated by its antioxidant, anti-inflammatory, and anti-apoptotic mechanisms hence may provide a successful agent for the management of ischemic stroke.
PMID: 26398383 [PubMed - in process]
Source: Pharmacological Reports - September 26, 2015 Category: Drugs & Pharmacology Authors: El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA Tags: Pharmacol Rep Source Type: research
Diabetes Drug May Help Prevent Second Stroke
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: WebMD Health - February 17, 2016 Category: Consumer Health News Source Type: news
Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: U.S. News - Health - February 17, 2016 Category: Consumer Health News Source Type: news
Diabetes Drug May Stop Stroke, Help Lipids
Pioglitazone may prevent repeated cardiovascular events in some patients. Combined with omega-3 fatty acids, the drug also can improve lipid metabolism.
Source: ConsultantLive - March 1, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Cardiovascular Diseases News Diabetes Source Type: news
The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
Source: Journal of Diabetes - June 7, 2016 Category: Endocrinology Authors: Silvio E. Inzucchi, Karen L. Furie Tags: Commentary Source Type: research
Actos After Stroke May Prevent Diabetes (CME/CE)
(MedPage Today) -- Treatment appears to stop progression from pre-diabetes
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news
Pioglitazone Slows Progression to Type 2 Diabetes: More IRIS DataPioglitazone Slows Progression to Type 2 Diabetes: More IRIS Data
New and previously reported data from the IRIS trial prompt discussion of reevaluating the role of now-generic pioglitazone in the treatment and prevention of diabetes and stroke. Medscape Medical News
Source: Medscape Diabetes Headlines - June 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
3 Drugs with the Most Severe Side Effects
Image Source
Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever.
The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news
Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies.
I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact.
Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications.
Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news
Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial - Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN.
CONTEXT: Pioglitazone reduces cardiovascular risk in non-diabetic patients after an ischemic stroke or transient ischemic attack (TIA) but is associated with increased risk for bone fracture. OBJECTIVE: To characterize fractures associated with pio...
Source: SafetyLit - December 17, 2016 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
